Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes.
In support of heterogeneity in Alzheimer's disease (AD), the existence of clinical and biologic subtypes has been claimed. We have investigated this claim by a statistical analysis of the relationships between the number of neurons in nucleus locus ceruleus (nLC), cortical levels of neurotransmitters, number of cortical plaques and tangles, and age. We separated AD patients into two groups: AD-1, with a less severe loss of nLC neurons; and AD-2, with a greater loss. The AD-2 cases were associated with less choline acetyltransferase activity, smaller concentrations of somatostatin and norepinephrine, and more plaques and tangles in the cerebral cortex. Although the mean age at death was less and the duration of dementia was greater in AD-2 patients than in AD-1 patients, the differences in these age-related variables were not significant. Further evidence of heterogeneity came from discriminant function analyses based on nLC neuronal counts and age at death. These findings, suggesting two subtypes of AD, suggest heterogeneity.
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D002452:Cell Count; D002540:Cerebral Cortex / Q000032:analysis / Q000473:pathology*; D002795:Choline O-Acetyltransferase / Q000032:analysis; D006801:Humans; D008125:Locus Coeruleus / Q000032:analysis / Q000473:pathology; D008875:Middle Aged; D009454:Neurofibrils / Q000473:pathology; D009638:Norepinephrine / Q000032:analysis; D013004:Somatostatin / Q000032:analysis
D013004:Somatostatin; D002795:Choline O-Acetyltransferase; D009638:Norepinephrine